This Brand File answers one question with evidence: who actually makes Thorne supplements, and can you trust the process behind them? Our method is simple: we only print what we verified this session against SEC filings, FDA databases, NSF's certification registry, and Thorne's own published statements, and we tell you plainly when something is not publicly disclosed.
Thorne is the practitioner-channel brand that went mainstream. It sells through doctors, sports teams, and its own site, and it charges accordingly. We have reviewed the products themselves in our full Thorne review. This page is about the company behind the label.
Quick facts
| Fact | What we verified |
|---|---|
| Founded | 1984, as Thorne Research, originally an Idaho company (SEC 10-K; FDA records list its old Dover, Idaho address) |
| Headquarters | Summerville, South Carolina, 620 Omni Industrial Blvd (SEC EDGAR registered address) |
| Parent company / ownership | Private equity firm L Catterton since October 2023; definitive agreement to be acquired by Procter & Gamble announced August 4, 2026, not yet closed as of August 2026 |
| Manufacturing | Own facility. Thorne manufactures in-house at its 272,000 sq ft Summerville plant (building leased, operations Thorne’s own, per 10-K) |
| Third-party testing | Facility cGMP certified through NSF since 2015; 40+ SKUs NSF Certified for Sport per NSF’s database; no public batch COAs |
| Recall & FDA history | One voluntary Class II recall (Captomer, 2014, DMSA) with an FDA consumer warning; no FDA warning letters found; nothing since |
| UV Transparency Score | 6/10 (rubric below) |
Who actually makes it
Thorne makes Thorne. That sentence sounds obvious until you learn how rare it is. Most supplement brands are marketing companies that hire contract manufacturers, and the only clue is small print on the label reading "Manufactured FOR" the brand rather than "Manufactured BY" it. That two-letter difference is the single fastest label check you can do on any supplement bottle: BY means the company named actually ran the machines, FOR means someone else did.
Thorne passes the check with unusually strong paperwork. Its final annual report as a public company, the FY2022 10-K filed with the SEC, states it flatly: "We manufacture our products in our 272,000-square-foot Summerville, South Carolina facility which is third-party certified as complying with Good Manufacturing Practice guidelines." A company can fudge marketing copy, but false statements in an SEC filing carry legal liability, which makes this about the best evidence class you can get for a manufacturing claim.
The historical record agrees. The FDA's enforcement database entry from Thorne's 2014 recall quotes the product label verbatim: "Manufactured By: Thorne Research, Inc., P.O. Box 25, Dover, Idaho." Thorne was physically making its own capsules back in its Idaho days too, so in-house production is not a recent marketing pose.
One honest nuance: Thorne does not own the building. The 10-K describes the Summerville plant as leased through October 2037, sitting on 25.8 acres, with a 115,500 square foot warehouse nearby and a 360,320 square foot expansion that was under construction next door. Leasing the real estate while running every machine inside it is normal industrial practice and does not change who makes the product. Thorne's own quality page now cites more than 735,000 square feet of manufacturing and warehouse space in total, a figure we could not independently verify but which is consistent with the leases disclosed to the SEC. The same filing says quality control runs through "two state-of-the-art laboratories" in-house, and the facility opened in 2019 after the company outgrew Idaho.
History and ownership
The company was founded in 1984 as Thorne Research, a small practitioner-only supplement maker whose name, according to its own SEC filing, was chosen to be a "thorn" in the side of the traditional supplement industry. The modern company really dates to 2010, when Paul Jacobson and his management team bought Thorne Research and began turning a niche practitioner brand into a consumer health company.
The ownership history since then has more chapters than most buyers realize, and every one below is sourced from SEC filings or the companies' own announcements:
In July 2018, two Japanese giants, Mitsui & Co. and Kirin Holdings, invested roughly $138.4 million in Series E preferred stock. The beer and trading conglomerates were Thorne's biggest outside backers before the public markets ever got a look. In 2021 Thorne merged with Onegevity, an AI health-testing startup Jacobson co-founded, and the combined Thorne HealthTech went public on September 23, 2021 on the Nasdaq Global Select Market under the ticker THRN, raising $70 million in gross proceeds. You will sometimes see the listing misreported as NYSE; the 10-K and the IPO announcements both say Nasdaq.
The public chapter was short. In August 2023 Thorne agreed to be taken private by L Catterton, the consumer-focused private equity firm, at $10.20 per share, roughly a $680 million deal. L Catterton completed the take-private on October 16, 2023, per its own press page, and the stock delisted.
Then came the big one. On August 4, 2026, Thorne announced a definitive agreement to be acquired by Procter & Gamble. The company's release names current CEO Colin Watts and says the deal is expected to close later in 2026, subject to regulatory approval. The release itself does not state a price; CNBC reported the figure at $3.8 billion, citing P&G's CEO. As of August 2026 Thorne is still owned by L Catterton, with P&G's purchase pending, and if the reported numbers hold, L Catterton will have roughly quintupled its money in three years. What P&G ownership means for formulas and pricing is genuinely unknown; the release contains no operational commitments, and we will update this file when the deal closes.
Testing and quality record
Thorne's testing story has a strong verified core and a soft edge. Start with the verified core. The Summerville facility has been cGMP certified through NSF International since 2015, per the SEC filing, meaning an independent auditor inspects the plant and its quality management system rather than taking the company's word for it. Thorne's site adds claims of an A rating from Australia's TGA and GRMA certification; those appear only as the brand's own statements, and we did not independently verify them this session.
The certification that matters most to buyers is per-product. NSF Certified for Sport tests specific SKUs, batch by batch, for label accuracy and around 280 banned substances. We checked NSF's own certified-product database rather than Thorne's marketing, and more than 40 Thorne SKUs currently hold NSF Certified for Sport status, including Creatine, Whey Protein Isolate, Amino Complex, Super EPA, Basic Nutrients, and, as of July 2026, Basic Prenatal. That is up from roughly 25 certified products in the 2022 SEC filing, so the program is expanding, not shrinking. The certification covers those specific products only; the rest of the 300+ product catalog relies on Thorne's internal four-round testing regime, which the company describes as running from raw material identity through shelf-life confirmation in its two in-house labs.
Now the soft edge. Thorne does not publish batch certificates of analysis for consumers to download, the way a brand like NOW or some sports brands increasingly do. Third-party accounts of what happens when you request a COA directly conflict: some reviewers report being declined, others describe Thorne as unusually forthcoming. We could not resolve this from public evidence this session, so we treat consumer COA access as not disclosed. For a company with two in-house labs and this much testing capacity, keeping the paperwork private is a choice, and it costs points below.
Recalls, warning letters, lawsuits
Here is the complete public record we could find, and how we searched it. We queried the openFDA food and drug enforcement databases for Thorne as a recalling firm, searched FDA warning letters, and swept news archives for lawsuits. The record contains exactly one significant FDA event, and it is worth understanding properly.
On June 12, 2014, the FDA issued a consumer alert, still readable in the agency's archived pages, warning people not to purchase or use Thorne Research's Captomer and Captomer-250. The products were marketed as dietary supplements for "heavy metal chelation" but contained DMSA, the active ingredient in a prescription drug for lead poisoning in children. The FDA said Thorne had received several adverse event reports associated with the products, and there are no FDA-approved over-the-counter chelation products at all. Thorne agreed to a voluntary recall, logged in the openFDA enforcement database as Class II recalls D-1383-2014 and D-1384-2014 (one record per product), with distribution across the US and six other countries. The reason field is blunt: marketed without an approved NDA/ANDA. The recall was completed and terminated, and selling a prescription-strength chelator as a supplement was a real compliance failure, whatever the company's practitioner-channel intentions were.
Since then, the file is clean. We found no Thorne recalls after 2014, no FDA warning letters addressed to Thorne Research or Thorne HealthTech, and no product-safety lawsuits in the news archives we searched. One caveat for completeness: a class-action marketing site reported a September 2025 cyber incident exposing customer data. We found no confirmation in any news outlet of record and no company statement, so we treat that claim as unconfirmed rather than established fact.
UV Transparency Score: 6/10
Here is the rubric, scored line by line against what we verified:
- Publishes COAs to consumers (+2): 0 of 2. No batch COAs are published, and third-party accounts of on-request access conflict. Not disclosed is a finding, and it is the biggest gap in an otherwise strong file.
- Names and operates own manufacturing facility (+2): 2 of 2. Named, located, sized, and sworn to in an SEC filing. Few brands in this industry clear the bar this cleanly.
- Third-party certification on core SKUs (+2): 2 of 2. Facility cGMP certification through NSF since 2015, plus 40+ SKUs in NSF's Certified for Sport database, verified at the source.
- Clear ownership disclosure (+1): 1 of 1. Every ownership change, including the pending P&G sale, was announced on Thorne's own press page with deal terms traceable through SEC filings.
- Clean recent recall record or exemplary handling (+1): 1 of 1. One recall in four decades, handled voluntarily in cooperation with the FDA, and twelve clean years since.
- Public response to testing controversies (+1): 0 of 1. We found no public Thorne statement addressing the 2014 Captomer episode, then or since. Cooperating with the FDA is not the same as explaining yourself to customers.
- Ingredient sourcing disclosure (+1): 0 of 1. "Globally sourced ingredients" and a No List of excluded additives are policies, not sourcing disclosure. Suppliers and countries of origin are not published.
A 6/10 puts Thorne in the upper tier of brands we have filed, held back almost entirely by paperwork it already generates but chooses not to publish.
The product range, mapped to our reviews
Thorne's catalog runs from practitioner staples to sports nutrition, and we have tested the flagships. Whether the whole line justifies its pricing is the question we work through in our Thorne supplements review. The practitioner-brand comparison most shoppers actually need is Thorne vs Pure Encapsulations, two brands with similar clinical positioning and very different manufacturing stories.
On the sports side, the NSF Certified for Sport creatine is the SKU that made Thorne a locker-room default; we put it head to head in Thorne creatine vs Momentous creatine. For the omega-3 line, Super EPA is one of the certified SKUs we verified in NSF's database, and our take on whether it beats cheaper fish oil is in is Thorne Super EPA worth it. And for the beauty-adjacent corner of the catalog, our Thorne collagen peptides review covers the powder that quietly became one of its best sellers.
FAQ
Who owns Thorne?
As of August 2026, private equity firm L Catterton, which took the company private in October 2023 for about $680 million. A definitive agreement for Procter & Gamble to acquire Thorne was announced on August 4, 2026, at a reported $3.8 billion, and the deal is expected to close later in 2026 pending regulatory approval.
Where is Thorne made?
In Thorne's own 272,000 square foot manufacturing facility in Summerville, South Carolina, which opened in 2019 and doubles as company headquarters. The company manufactures in-house rather than using contract manufacturers, a claim we verified in its SEC annual report, not just its marketing.
Is Thorne NSF certified?
Yes, twice over. The facility has held NSF cGMP certification since 2015, and more than 40 individual products carry NSF Certified for Sport, which we confirmed in NSF's own database. The Sport certification applies per SKU, not to the whole catalog.
Has Thorne ever been recalled?
Once. In June 2014 the FDA warned consumers about Captomer and Captomer-250, chelation products containing the prescription drug ingredient DMSA, and Thorne voluntarily recalled them. We found no recalls, FDA warning letters, or safety lawsuits since, based on searches of FDA enforcement databases and news archives this session.
Does Thorne publish test results?
Not in the form that matters most. The company describes four rounds of internal testing and holds real third-party certifications, but batch certificates of analysis are not published for consumers, and public accounts conflict on whether Thorne releases them on request. That gap is why it scores 6/10 rather than 8/10 on our transparency rubric.
The bottom line
Strip away the branding and Thorne is exactly what it claims to be: a company that formulates, manufactures, and tests its own supplements in a facility it operates and discloses, with the SEC paperwork to prove it. That puts it in a small minority of the supplement industry, and it is the main reason the products survive scrutiny in our reviews.
The honest caveats are three. The 2014 Captomer recall was a genuine regulatory failure, even if it is now twelve years old. Batch test results stay locked inside the building. And the company is about to change hands for the third time in five years, this time to Procter & Gamble, which means the culture that built all of the above will soon answer to a new owner. Buy Thorne for what it verifiably is today, and check back on this file after the deal closes.
